This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

7 - 9 November 2022
RAIAmsterdam

Michael Zoerer
Senior Group Leader, Clinical Operations at AOP Orphan Pharmaceuticals AG

Profile

Michael is responsible for a team of 11 people and the overall delivery of the conducted studies. The group runs several studies in different indications with a clear focus on rare diseases. In 2016 AOP Orphan received approval for one new product (RAPIBLOC®). In 2019 AOP received the marketing authorization for their first biological (BESREMi®), after completing a series of clinical studies and successfully passing a series of EMA inspections under Michael’s responsibility.

Before joining AOP Orphan Michael has been operations manager for Haemophilia at Baxter.
Michael has many years of experience as a project manager and learned the job in clinical research from scratch starting as CRA at Amgen.
Michael received his Ph. D in biochemistry from the University of Vienna.

Agenda Sessions

  • PANEL: David and Goliath – Is There Still a Place for Small to Mid-sized CROs in Today’s Complex Clinical Trial Arena?

    14:00
  • Real World Evidence using Non- interventional studies

    15:40